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Abstract: Increase of VPAC receptor s binding to the 16γ -glutamyl diaminopropane vasoactive intestinal peptide (VIP-DAP)
agonist, a vasoactive intestinal polypeptide (VIP) structural analogue containing a positive charge at position 16, has confirmed
the importance of a positive charge at this site. By investigating the effect of distance from the peptide backbone Cα of a
positive charge in position 16, data are reported here concerning: (i) a novel chemical method used for the synthesis of a new
family of 16γ -glutamyl diamine VIP derivatives differing among them for single carbon atoms and including diaminoethane (VIP-
DAE2), diaminopropane (VIP-DAP3), diaminobutane (VIP-DAB4), diaminopentane (VIP-DAP5), and diaminohexane (VIP-DAH6);
(ii) functional characterization of these compounds on human VPAC1 and VPAC2 receptors. In more detail, the EC50 and IC50
values, when measured as a function of the alkylic chain length, show in more detail, that the use of VIP-DAB4 derivative changes
the IC50 but not the EC50, thus indicating on hVPAC2 receptor an unexpected relationship between binding and activity that
differs from that obtained on hVPAC1. Copyright  2007 European Peptide Society and John Wiley & Sons, Ltd.
Keywords: glutamate polyamination; chemical synthesis; VIP diamino derivatives; human VIP receptors function
INTRODUCTION
The vasoactive intestinal polypeptide (VIP) is a 28-
aminoacid long peptide that serves the function of
hormone, neurotransmitter, and immunomodulator
in mammals and other vertebrates [1]. VIP exerts
its biological effects by interaction with two distinct
natural class II G protein-coupled receptors (GPCRs)
VIP/PACAP 1 (VPAC 1) and VIP/PACAP 2 (VPAC
2), which transduce the ligand signal through the
activation of different enzymatic effector systems, such
as adenylate cyclase, phospholipase C, and iNOS [2–4].
Work is more advanced on the mechanism of ligand
binding and activation of class I GPCR, that use
relatively small molecules as ligands. In contrast,
fewer results are available in the case of class II
GPCRs, peptide receptors that have much larger ligands
and that exhibit greater conformational flexibility. The
detailed signaling mechanism of VIP receptors and their
physiological role are currently investigated. The only
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structural information available on VIP and its related
peptides has been mainly obtained by CD and NMR
analyses [5].
Structure–activity studies, performed on a number
of analogues and VIP fragments, demonstrated that
full action of VIP is critically dependent upon integrity
of the entire molecule [6–8]. More precisely, the N-
terminal helix is known to be critical for the high affinity
binding and human VPAC1 (hVPAC1) and human
VPAC2 (hVPAC2) discrimination [9–12]. Concerning the
VIP central region, Robberecht and coll. demonstrated
the unexpected importance of the aminoacid at position
16 in this region on its interaction with the receptor N-
terminal domain [13]. In order to investigate the effect
of a positive charge at position 16 on VPAC receptors
activity we used the transglutaminase (TGase) to modify
the primary structure of VIP by poliaminating Gln16
with a variety of amines of different carbon chain length
and positive charge, both in rats and humans [14–16].
The functional characterization of three polyaminated
VIP derivatives has demonstrated their ability to act
as ‘super’ (VIPDap) or ‘weak-full’ (VIPSpd and VIPSpm)
agonists on VPAC receptors [17]. Recently, the stability
of VIPDap analogue has been evaluated in experiments of
Copyright  2007 European Peptide Society and John Wiley & Sons, Ltd.
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limited proteolysis [18]. The data obtained have shown
that this peptide has a structural stability higher than
VIP, associated to an increased biological activity on
cell systems [19]. The role played by the different VIP
residues in the recognition and activation of VIP natural
receptors has been revised in the light of peptide agonist
docking on to the N-terminal ectodomain of hVPAC1
receptor, how recently established by photoaffinity,
NMR, and molecular modeling studies [20].
In this paper, we plan to evaluate on hVPAC1 and
hVPAC2 functional activity the effect of the distance
of the positive charge from VIP Cα in position 16
by progressively increasing by single carbon atom the
alkyl chain of the VIP 16γ -glutamyl diamino conjugated.
To obtain the appropriate molecular modification of
VIP, we replaced the original enzimatic, TGase-based,
method with a novel chemical, faster, more practical,
and less expensive protocol to synthesize the five
different VIP γ -glutamyl derivatives used in this paper.
MATERIALS AND METHODS
Chemical Synthesis of VIP-16γ -Glutamyl Derivatives
Materials and general procedures. All solvents were
purchased from Carlo Erba (Rodano, Milan, Italy). Extraction
solvents were dried over sodium sulfate. Solvents used
for reactions were dried over 3 A˚ molecular sieves. All
the solvents were filtered and degassed prior to use.
Reagent grade materials were purchased from Bachem
(Bubendorf, Switzerland), Inalco-Novabiochem (Milan, Italy)
and from Aldrich (Milan, Italy) and were used without further
purification. Thin layer chromatography was performed
on precoated silica gel Durasil-25 UV254 (Macherey-Nagel,
Germany) plates. The compounds were detected on thin layer
chromatography plates by UV light and ninhydrin. Molecular
weights of final peptides were assessed by electrospray
ionization mass spectrometry (ESI-MS) on a ThermoFinnigan
LCQ Ion-Trap. Aminoacid analyses were carried out using
PITC methodology (Pico-Tag, Waters-Millipore, Waltham, MA).
Lyophilized samples of peptides (50–100 pmol) were placed
in heat-treated borosilicate tubes (50 × 4 mm), sealed, and
hydrolyzed using 200 µl of 6 N HCl containing 1% phenol
in the Pico-Tag work station for 1 h at 150 °C. A Hypersil
ODS column (250 × 4.6 mm, 5 µm particle size) was employed
to separate the PITC-aminoacid derivatives. Reversed–phase
purification was routinely performed on a Waters Delta-Prep
4000 system equipped with a Waters 484 multiwavelength
detector on a Vydac C18 silica (15–20 µm, 22 × 5000 mm)
high performance liquid chromatography (HPLC) column. The
operational flow rate was 60 ml/min. Homogeneity of the
products was assessed by analytical reversed-phase HPLC
using a Vydac C18 column (5 µm, 4.6 × 250 mm); UV detection
at 220 nm, flow rate 1 ml min−1. The column was connected to
a Rheodyne model 7725 injector, a Waters 600 HPLC system,
a Waters 486 tunable absorbance detector set to 220 nm, and
a Waters 746 chart recorder.
Unconventional aminoacids synthesis. These compounds
(4a–4e) were prepared following the procedure reported in
Figure 1. H-Glu-OBzl (1) was dissolved in 9% Na2CO3 and
a solution of N-(9-fluorenylmethoxycarboniloxy)succinimide
(Fmoc-Osu) in DMF was added dropwise. The obtained Fmoc-
Glu-OBzl [21] (2) was condensed with the appropriate tert-
butyl aminoalkylcarbamate [NH2-(CH2)n-NH-Boc where n = 2,
3, 4, 5 or 6] using DCC/HOBt as coupling reagents to obtain
intermediates 3a–3e. Hydrogenation with 5% palladium on
activated carbon (Pd/C) in methanol produced the desired
final aminoacid derivatives 4a–4e that were purified by silica
gel column chromatography and crystallization.
Fmoc-Glu-OBzl (2). H-Glu-OBzl (1) (3.0 g, 0.0126 mol) was
suspended in 25 ml of 9% Na2CO3 and cooled in ice water.
A solution of Fmoc-OSu (4.7 g, 0.014 mol) in 25 ml of DMF
was then added dropwise and the mixture was stirred at
room temperature (r.t.) for 5 h. The solvent was evaporated
and the residue, diluted with water, was acidified to pH
2 with 2 N H2SO4. Chloroform was then added and the
collected organic phase was dried on anhydrous Na2SO4
Figure 1 Procedure for the synthesis of unnatural residues 4a–4e.
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and evaporated. Crystallization from n-hexane generated the
desired pure product as a white solid: yield 5.5 g (95%).
Fmoc-Glu[NH(CH2)2NHBoc]-OH (4a). DCC (0.6 g, 2.9 mmol)
was added portionwise to an ice-cold solution of Fmoc-Glu-
OBzl (2, 1.2 g, 2.6 mmol) and HOBt (0.4 g, 2.9 mmol) in DMF
(25 ml). After completing the addition, the reaction mixture
was stirred at 0 °C for 15 min and then (2-aminoethyl)carbamic
acid tert-butyl ester (0.42 g, 2.6 mmol) was added. The
solution was stirred at r.t. overnight; DCU was filtered off
and the solvent was removed in vacuo. The residue was
dissolved in ethyl acetate and washed with 5% NaHCO3,
10% citric acid, and brine. The organic phase was dried on
anhydrous Na2SO4 and evaporated in vacuo. The intermediate
Fmoc-Glu[NH(CH2)2NHBoc]-OBzl (3a) was precipitated with
diethyl ether and dissolved in methanol (40 ml). The obtained
solution was hydrogenated at 2 atm at r.t. for 30 min in
presence of 5% Pd/C (130 mg). After completion of the
reaction, the mixture was filtered on celite and the solvent was
removed in vacuo. The pure product 4a was crystallized from
diethyl ether/n-hexane: yield (calculated on two steps) 0.95 g,
73%. mp 133–135 °C. ESI-MS (MW 511.6): 512.2 [M + H+].
Elemental analysis: calcd for C27H33N3O7: C, 63.39%; H,
6.50%; N, 8.21%; obtained: C, 63.52%; H, 6.51%; N, 8.03%.
Using the above described procedure for the preparation
of 4a, the following additional derivatives (4b–4e) were
synthesized using as starting material Fmoc-Glu-OBzl (2)
and (3-amino-propyl)-carbamic acid tert-butyl ester, (4-
amino-butyl)-carbamic acid tert-butyl ester, (5-amino-pentyl)-
carbamic acid tert-butyl ester and (6-amino-hexyl)-carbamic
acid tert-butyl ester, respectively:
Fmoc-Glu[NH(CH2)3NHBoc]-OH (4b). Yield 70%. mp 114-
116 °C. ESI-MS (MW 525.6): 526.4 [M + H+]. Elemental
analysis: calcd for C28H35N3O7: C, 63.98%; H, 6.71%; N,
7.99%; obtained: C, 63.78%; H, 6.84%; N, 7.97%.
Fmoc-Glu[NH(CH2)4NHBoc]-OH (4c). Yield 75%. mp 110-
112 °C. ESI-MS (MW 539.6): 540.8 [M + H+]. Elemental
analysis: calcd for C29H37N3O7: C, 64.55%; H, 6.91%; N,
7.79%; obtained: C, 64.61%; H, 6.89%; N, 7.81%.
Fmoc-Glu[NH(CH2)5NHBoc]-OH (4d). Yield 77%. mp 104-
106 °C. ESI-MS (MW 553.6): 554.5 [M + H+]. Elemental
analysis: calcd for C30H39N3O7: C, 65.08%; H, 7.10%; N,
7.59%; obtained: C, 64.90%; H, 7.12%; N, 7.61%.
Fmoc-Glu[NH(CH2)6NHBoc]-OH (4e). Yield 73%. mp 94-
96 °C. ESI-MS (MW 567.7): 568.6 [M + H+]. Elemental analysis:
calcd for C31H41N3O7: C, 65.59%; H, 7.28%; N, 7.40%;
obtained: C, 65.40%; H, 7.31%; N, 7.38%.
Peptide synthesis. Compounds I–V were prepared by solid
phase peptide synthesis on 0.1 mmol of a Rink amide MBHA
resin (0.78 mmol/g substitution grade) using a Milligen 9050
peptide synthesizer. Fmoc was employed as α-amino protecting
group and TBTU/HOBt/NMM in DMF/N-methylpyrrolidone
(NMP) (1/1) were applied to the coupling reactions. Four times
excess of each aminoacid was used and double coupling and
extended coupling time were employed when Val19, Ala18,
Met17, Lys15, Phe6, Val5, Ala4 and unnatural derivatives
4a–4e were incorporated; capping was accomplished with
20% acetic anhydride in DMF. Cleavage of N-Fmoc protecting
group, using 25% piperidine (v/v) in DMF/NMP (1/1), was
monitored at each stage by measuring the absorbance of the
liberated N-(9-fluorenylmethyl)piperidine. Protected peptidyl
resins were treated with 20 ml of TFA/triethylsilane/H2O
(90/7/3) at r.t. for 2 h; the mixture was filtered and the
resin washed with TFA/CH2Cl2 (1/1). The combined filtrate
and washings were evaporated and the free peptides, I–V,
precipitated with diethyl ether. The crude material was purified
by preparative HPLC on a Vydac C18 column (15–20 µm, 22 ×
5000 mm) employing the following conditions: eluent A, 0.1%
TFA (v/v) in water; eluent B, 0.1% TFA(v/v) in acetonitrile;
linear gradient 0–35% B over 60 min. Homogeneity of the
products was assessed by analytical reversed-phase HPLC
using a Vydac C18 column (5 µm, 4.6 × 250 mm) employing the
following conditions: eluent A, 0.05% TFA (v/v) in water; eluent
B, 0.05% TFA(v/v) in acetonitrile; linear gradient 0–40% B over
35 min. Structural verification of the final desired peptides I–V
was achieved by aminoacid analysis and mass spectrometry
(Tables 1 and 2).
Molecular Modeling
Molecular models of the aminoacids glutamine, arginine,
glutamate and their glutamyl derivatives have been created
with the Insight II package (Accelrys, San Diego, CA). The
Builder module and its tools have been used to modify the
side chain by adding the appropriate number of C atoms
and hydrogen atoms. The amino and carboxyl terminals
were blocked with an acetyl group at the N-term and an
amidic group at the C-term to avoid terminal charge effects.
Finally, an energy minimization procedure has been applied to
optimize the geometry, according to the standard settings of
the optimize option of the package. Distances also have been
measured with the package tools.
CHO Cell Line Culture
The recombinant Chinese Hamster Ovary (CHO) cells express-
ing the rat or human recombinant VPAC1 and VPAC2 recep-
tors were prepared in Prof. P. Robberecht’s laboratory. Cells
were maintained in α-minimal essential medium (α-MEM),
supplemented with 10% FCS, 2 mM L-glutamine, 100 µg ml−1
penicillin and 100 µg ml−1 streptomycin with an atmosphere
of 95% air and 5% CO2 at 37 °C. Geneticin (0.4 mg ml
−1) was
maintained in the culture medium of the stock culture. Sub-
cultures prepared for membrane purification were done in a
medium without geneticin.
Membrane Preparation, Ligand Binding (IC50), and
Adenylate Cyclase Activity (EC50) Determination
An appropriate number of CHO cells was harvested with a
rubber policeman and pelleted by low speed centrifugation, the
supernatant was discarded and the cells were lysed in 1 mM
NaHCO3 and quick freezing in liquid nitrogen. After thawing,
the lysate was centrifuged at 4 °C for 10 min at 400 × g and
the supernatant was further centrifuged at 20 000 × g for
10 min. The final pellet was resuspended in 1 mM NaHCO3
and used immediately as a crude membrane preparation.
[125I]VIP (specific radioactivity: 0.7 mCi mmol−1) was used
as tracer for the identification of both rat or human VPAC1
receptors; [125I]Ro 25–1553 (specific radioactivity: 0.8 mCi
mmol−1) was used as tracer for labelling both rat and human
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Table 1 Sequence and MS analysis of VIP analogues I–V
Compa Sequence MW
Calcdb Found
I HSDAVFTDNYTRLRKQ[(CH2)2NH2]MAVKKYLNSILN 3368.9 3369.2
II HSDAVFTDNYTRLRKQ[(CH2)3NH2]MAVKKYLNSILN 3382.9 3383.7
III HSDAVFTDNYTRLRKQ[(CH2)4NH2]MAVKKYLNSILN 3397.0 3398.0
IV HSDAVFTDNYTRLRKQ[(CH2)5NH2]MAVKKYLNSILN 3411.0 3411.5
V HSDAVFTDNYTRLRKQ[(CH2)6NH2]MAVKKYLNSILN 3425.1 3425.8
a Compound.
b Calculated.
Table 2 Analytical data of VIP analogues I–V
Compa Aminoacid analysisb HPLCc
H S D A V F T Y R L K I
I 1.03 1.81 4.65 1.96 1.94 0.96 1.89 1.87 1.81 2.84 2.94 0.89 19.1
II 0.98 1.90 4.85 1.90 2.02 0.94 1.91 1.94 1.96 2.93 2.83 0.91 19.3
III 1.01 1.85 4.93 2.07 1.89 1.04 1.94 1.99 1.84 2.87 2.97 0.94 19.9
IV 0.86 1.82 4.99 1.86 1.98 0.96 1.99 1.85 1.85 3.01 2.91 0.99 20.2
V 0.85 1.84 4.87 2.01 1.87 1.03 2.01 1.95 1.92 3.02 3.02 1.01 20.1
a Compound.
b The method used for hydrolysis does not allow the recovery of methionine, while asparagine is completely converted to aspartic
acid.
c Retention time for the following conditions: reversed phase, Vydac C18 column (5 µm, 4.6 × 250 mm) and the following gradient
system: A, 0.1% TFA in CH3CN; B, 0.1% TFA in H2O; linear gradient from 0% A–100% B to 60% A–40% B over 25 min, UV
detection at 220 nm, flow rate 1 ml/min.
VPAC2 receptors [22]. The binding of labelled ligands to
CHO purified membranes was performed as described [9];
in all the cases the nonspecific binding was defined as the
residual binding in the presence of 1 µM VIP. Competition
curves were carried out by incubating membranes and tracer
in the presence of increasing concentrations of unlabelled
peptides. Peptide potency was expressed as IC50 value, i.e. as
the peptide concentration required for half maximal inhibition
of tracer binding. In detail, the binding was performed at 37 °C
in a buffer containing 20 mM Tris-maleate (pH 7.4), 2 mM
MgCl2, 0.1 mg ml
−1 bacitracin and 1% BSA; 3–30 protein
was used per assay. The bound was separated from the
free? radioactivity by filtration through glass fiber filters GF/C
presoaked for 24 h in 0.1% polyethyleneimine and rinsed three
times with a 20 mM phosphate buffer (pH 7.4) containing 1%
BSA. Adenylate cyclase activity was determined by a previously
published technique [23]. Membrane proteins (3–15 mg) were
incubated in a total volume of 60 µl containing 0.5 mM [γ -
32P]ATP, 10 µM GTP, 5 mM MgCl2, 0.5 mM EGTA, 1 mM cAMP,
1 mM theophylline, 10 mM phosphoenolpyruvate, 30 µg ml−1
pyruvate kinase, and 30 mM Tris-HCl at a final PH of 7.5.
The reaction was initiated by membrane addition and was
terminated after a 12-min incubation at 37 °C by adding 0.5 ml
of stopping buffer (0.5% SDS, 0.5 mM ATP, 0.5 mM cAMP,
20 000 cpm of [83H] cAMP). cAMP was separated from ATP
by two successive chromatographies on Dowex 50-WX8 and
neutral alumina.
Statistical Analysis
The data were expressed as the mean ± standard error of
the mean (SEM) obtained from three separate experiments.
Each experiment included eight samples, each sample being
performed in triplicate. One-way analysis of variance (ANOVA)
was used to assess statistical significance between means.
Differences between means were considered significant when
p < 0.05 using the Bonferroni post-test. All statistical analyses
were performed with the GraphPad Instant software (Intuitive
Software for Science, San Diego, CA).
RESULTS AND DISCUSSION
Unnatural Aminoacids – Chemical Synthesis
The unnatural aminoacid derivatives 4a–4e, employed
for the chemical synthesis of VIP analogues I–V,
have been prepared following the procedure reported
in Figure 1. Commercially available H-Glu-OBzl (1)
was converted to the corresponding Fmoc derivative
(2) by means of Fmoc-OSu in 9% Na2CO3 and DMF
solution. The obtained Fmoc-Glu-OBzl (2) was reacted
with the appropriate tert-butyl aminoalkylcarbamate
[NH2 –(CH2)n –NH–Boc where n = 2, 3, 4, 5 or 6] using
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DCC/HOBt as coupling reagents to give intermediates
3a–3e. Hydrogenation with 5% palladium on activated
carbon (Pd/C) in methanol, at r.t. for 30 min, removed
the Nα-benzyl ester protecting group furnishing the
desired final Fmoc aminoacid derivatives, 4a–4e, that
were purified by silica gel column chromatography and
crystallization. Some difficulties have been encountered
in the synthesis of 28 residues peptides (I–V) primarily
because of the presence of aminoacids (such as
Arg, Met and Tyr) that are prone to undergoing
side reactions during either the coupling steps or
the final deprotection and also because of sequences
that may be considered problematic (Ala4-Val5-Phe6
and Met17-Ala18-Val19). Peptide synthesis was carried
out on a continuous-flow Milligen 9050 peptide
synthesizer using a Rink amide MBHA resin. Fmoc
was employed as α-amino protecting group utilizing
two pre- and post-column UV detectors to measure the
absorbance of the solution flowing through it obtaining
a feedback monitoring of each step of the synthetic
process. Several protocols have been used, differing in
employed coupling reagents and reaction times; the
quality of the syntheses was examined following the
incorporation of every five residues via HPLC and ESI-
MS of the crude product obtained by cleavage of an
aliquot of peptidyl resin with TFA/triethylsilane/H2O
(90/7/3). The following protocol, optimized with the
synthesis of native VIP sequence, gave the best results:
(i) four times excess of each residue was employed,
TBTU/HOBt/NMM as coupling reagents in DMF/NMP
(1/1); (ii) double coupling and extended coupling times
were employed for Val19, Ala18, Met17, Lys15, Phe6, Val5,
Ala4 and unnatural derivatives 4a–4e; (iii) extended
time for Fmoc removal (15 min instead of 7 min)
was used when slow Fmoc removal was observed;
(iv) capping was accomplished for every four residues
with 20% acetic anhydride in DMF. Finally, the cleavage
of the peptides from the resin was effected using a
mixture of TFA/triethylsilane/H2O (90/7/3). All the
final compounds, purified by RP-HPLC to greater than
98% purity, gave satisfactory aminoacids analyses and
were characterized by ESI-MS (Tables 1 and 2).
Structural Models of Diamino Glutamates Used in VIP
Modification
The structural model of both the different neo-
synthesized diamino glutamates and the lateral chain
of glutamine, glutamate, and arginine are reported in
Figure 2. In more detail, the distance of the positive
charge from the Cα at VIP position 16, is reported in
Table 3.
Figure 2 Structural models of the neo-synthesized VIP derivatives interacting with human VPAC1 and VPAC2 receptors.
D = Distance (A˚) of Z+ from 16Cα.
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Table 3 IC50 and EC50 values of some VIP analogues, polyaminated at position 16 with polyamines of different length, following
binding to hVPAC1 or hVPAC2
Aminoacid at Vip Distance (A˚) of hVPAC1 hVPAC2









GLN 4.72 1.63 ± 0.26 0.87 ± 0.01 1.93 ± 0.26 1.17 ± 0.03
GLU (Z−) 4.72 10.81 ± 0.27 4.03 ± 0.21 10.21 ± 0.27 5.35 ± 0.07
ARG 7.07 0.61 ± 0.27 0.54 ± 0.08 2.32 ± 0.27 3.08 ± 0.04
γGLUa-DAE2 5.85 0.85 ± 0.26 0.69 ± 0.10 3.55 ± 0.27 1.67 ± 0.04
γGLUa-DAP3 7.42 0.68 ± 0.26 0.46 ± 0.09 3.42 ± 0.27 1.57 ± 0.04
γGLUa-DAB4 7.70 1.22 ± 0.27 0.66 ± 0.11 3.19 ± 0.28 2.35 ± 0.05
γGLUa-DAP5 9.25 0.85 ± 0.26 0.45 ± 0.09 2.57 ± 0.27 1.08 ± 0.06
γGLUa-DAH6 9.82 0.86 ± 0.26 0.43 ± 0.14 2.06 ± 0.26 0.86 ± 0.06
a γGLU- : γglutamyl-.
Effect of VIP 16γ –Glutamyldiamino Derivatives Z+ on
VIP Receptors Functional Activity
In Table 3 are reported the EC50 and IC50 values for
hVPAC1 and hVPAC2, respectively, as a function of the
distance of positive charge from VIP Cα at position 16.
In particular, for hVPAC1 the EC50 and IC50 patterns
are remarkably similar, in that the receptor activity
mirrors the ligand binding events (Figure 3, left panel).
Different results were, in contrast, obtained for hVPAC2
(Figure 3, right panel): EC50 and IC50 patterns are not
overlapping because the IC50 of VIP-DAB4 does not
reflect its EC50.
The polyamination of Gln16 side chain significantly
modulates the ability of VIP to bind and stimulate the
hVPAC1 receptor functional activity [17]. This finding
supports Robberecht’s data indicating the critical role
played by the presence of the positively charged arginine
at position 16 of VIP polypeptide chain [13]. In addition,
the possibility that the side chain length could play
an important role in modulating the receptor binding
ability and activity is supported by the IC50 and
EC50 data, demonstrating a better VIP-Dap functional
activity in comparison with VIP, VIP-SPD, and VIP-SPM.
Previous work has also showed that in comparison
with VIP, VIP-DAP3 possesses a better functional and
biological activity on hVPAC1 receptor, probably as a
mirror of its higher structural stability [18,19]. The
possible existence in the receptor of different dynamic
conformational states corresponding to different states
of activation [24,25], allows us to hypothesize that
the presence at position 16 of a positive charge,
associated with possible hydrophobic interactions and
a definite side chain length, could be effective in
stabilizing a conformational state corresponding to the
highest binding affinity with or without change in
receptor activity. The hypothesis that a positive charge
at the position 16 of VIP could play an important
role in the ligand–receptor recognition mechanism, is
also supported by the published data on the charge
distribution in VPAC receptor aminoacid sequence [17].
Figure 3 IC50 and EC50 patterns produced by VIP analogues polyaminated at position 16 with polyamines of different lengths.
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In this paper, we have reported data showing a novel
chemical method for the synthesis of a family of VIP
analogues (five distinct diamino derivatives different
among them for a single carbon atom), aiming at
analyzing the effects of the positive charge distance
from the VIP Cα at position 16 on VIP receptor
activity. For the synthesis of these compounds, a
chemical technique was substituted for our previous
enzymatic method with TGase: this novel technique
is faster, less expensive, and more flexible for the
pharmacological analysis. The chemical modification is
performed, before the synthetic step, on a glutamic acid
residue that is then inserted in the polypeptide chain
sequence at position 16. In contrast, in the enzymatic
TGase catalyzed synthesis the VIP is first incubated
with the enzyme in the presence of the diamines to
allow the formation of the VIP-γ -derivative, the latter
being then separated from the unmodified VIP by HPLC
and purified.
The analysis of the atomic distances evaluated by
using computational models of the lateral chains
(Figure 2), has shown for VIP-DAP3 a distance of of
7.42 A˚ for the positive charge Z+ from the Cα at position
16. Starting from this distance, we have analyzed the
effect of Z+ on the hVPAC1 and hVPAC2 receptors
in a range of about 4 A˚, i.e. from the 5.85 A˚ of
VIP-DAE2 to the 9.82 A˚ of VIP-DAH6. By analyzing
the functional effects (IC50 and EC50) of the neo-
synthesized analogues on VIP receptors as a function of
the progressive increase in length of the lateral chains,
a significant difference was found between hVPAC1
and hVPAC2 receptors. In particular, a comparable
pattern of EC50 and IC50 was clearly detectable for
the hVPAC1 receptor with a clear peak appearing when
Z+ was at a distance of 7.70 A˚ (see VIP-DAB4). In
this case, the ligand binding to hVPAC1 significantly
(p < 0.05) changes as a distance function of VIP-DAP3
(7.25 A˚) and VIP-DAP5 (9.25 A˚) with 80 and 40%
IC50 increase, respectively. In line with this finding,
the EC50 increase was higher than 40% for these
two homologues (Table 3 and Figure 3). In contrast,
hVPAC2 shows a progressive IC50 decrease as function
of carbon chain length increase. On the other hand,
on the same receptor the EC50 pattern differs for the
presence of a peak at the same 7.70 A˚ distance (VIP-
DAB4) as in the case of hVPAC1 receptor, with a 50%
(VIP-DAP3) and a 118% (VIP-DAP5) increase in EC50,
respectively (Table 3 and Figure 3). Furthermore, on
hVPAC2 the IC50 of VIP-DAH6 appears comparable
with that of VIP, although there is a significant increase
(26%) of functional activity (EC50), showing for the first
time that the occurrence of a positive charge in position
16 can generate a better agonist of hVPAC2 receptor.
This finding suggests that a further increase in the
length of lateral chain could results in a superagonist
production. At present, the syntheses of additional 16γ -
glutamyl diamino VIP derivatives, possessing different
lengths and compositions, are in progress for a more
complete analysis of their functioning.
Taken together, all these data suggest: (i) the
possibility to discriminate hVPAC1 from hVPAC2 on the
basis of their different IC50, but not EC50, patterns;
(ii) a different structural interaction between the VIP-
DAB4 ligand and the two distinct receptor domains
involved in ligand binding and functional activation
of both receptors, the activation module of hVPAC2
receptor acting probably independent from the binding
module; (iii) the possibility that position 16 of the VIP,
even if actually used in the best hVPAC1 agonists
and antagonists when substituted with arginine, could
be used, if appropriately modified, in agonists and/or
antagonists of hVPAC2 receptor.
CONCLUSIONS
We have synthesized a novel family of VIP analogues
including five distinct diamino derivatives differing
among them for a single carbon atom (see above)
aiming at analyzing the effects of the positive charge
distance from the Cα at position 16 on receptor
activity. For the synthesis of these compounds, a
novel chemical technique was used in place of our
previous enzymatic method with TGase. This technique
was found to be faster, less expensive, and more
flexible for pharmacological analysis. By investigating
the effect of the positive charge distance from the
peptide backbone Cα, we have reported here the data
concerning the functional characterization of these 16γ -
glutamyl diamino VIP derivatives with human VPAC1
and VPAC2 receptors. More precisely, we have found
that the EC50 and IC50 analysis, when evaluated
as function of their alkylic chain length, shows that
the VIP-DAB4 derivative alters IC50 but not EC50,
thus indicating with hVPAC2 receptor an unexpected
relationship between binding and activity that differs
from that obtained with hVPAC1.
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